Enlivex Therapeutics Ltd. (ENLV) DCF Valuation

Valoración de DCF de Enlivex Therapeutics Ltd. (Enlv)

IL | Healthcare | Biotechnology | NASDAQ
Enlivex Therapeutics Ltd. (ENLV) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Enlivex Therapeutics Ltd. (ENLV) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Evalúe la perspectiva financiera de Enlivex Therapeutics Ltd. (LIVR) como un experto! Esta calculadora DCF (enlv) le proporciona datos financieros precipitados y la libertad de modificar el crecimiento de los ingresos, WACC, los márgenes y otros supuestos esenciales para alinearse con sus predicciones.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 2.3 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 -100 0 0 -25 -25 -25 -25 -25
EBITDA -9.1 -9.5 -18.7 -25.0 -28.2 .0 .0 .0 .0 .0
EBITDA, % 100 -417.17 100 100 100 60 60 60 60 60
Depreciation .3 .3 .5 .8 .8 .0 .0 .0 .0 .0
Depreciation, % 100 12.56 100 100 100 82.51 82.51 82.51 82.51 82.51
EBIT -9.4 -9.8 -19.3 -25.8 -29.1 .0 .0 .0 .0 .0
EBIT, % 100 -429.73 100 100 100 60 60 60 60 60
Total Cash 12.0 35.7 84.1 48.1 27.3 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables -1.1 .0 1.1 .0 .0
Account Receivables, % 100 0 100 100 100
Inventories 1.5 -31.2 -12.2 1.2 .0 .0 .0 .0 .0 .0
Inventories, % 100 -1370.14 100 100 100 60 60 60 60 60
Accounts Payable .3 .5 .9 1.9 .8 .0 .0 .0 .0 .0
Accounts Payable, % 100 20.33 100 100 100 84.07 84.07 84.07 84.07 84.07
Capital Expenditure -.2 -1.0 -1.6 -8.1 -.2 .0 .0 .0 .0 .0
Capital Expenditure, % 100 -44.75 100 100 100 -8.95 -8.95 -8.95 -8.95 -8.95
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -10.1 -11.5 -12.9 -35.2 -29.1 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -10.1 19.5 -33.6 -53.8 -28.4 -.8 .0 .0 .0 .0
WACC, % 9.43 9.43 9.37 9.43 9.43 9.42 9.42 9.42 9.42 9.42
PV UFCF
SUM PV UFCF -.8
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -1
Net Debt 0
Equity Value -1
Diluted Shares Outstanding, MM 19
Equity Value Per Share -0.05

What You Will Get

  • Real Enlivex Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Enlivex Therapeutics Ltd. (ENLV).
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to fit your analysis.
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Enlivex’s fair value.
  • Versatile Excel Template: Designed for quick edits, scenario testing, and detailed projections specific to Enlivex Therapeutics Ltd. (ENLV).
  • Time-Saving and Accurate: Skip building models from scratch while ensuring precision and flexibility in your financial analysis.

Key Features

  • Comprehensive DCF Model: Features both unlevered and levered DCF valuation frameworks tailored for Enlivex Therapeutics Ltd. (ENLV).
  • WACC Analysis Tool: Pre-configured Weighted Average Cost of Capital template with adjustable parameters.
  • Customizable Forecast Inputs: Adjust growth projections, capital investments, and discount rates as needed.
  • Integrated Financial Metrics: Evaluate profitability, debt levels, and operational efficiency ratios specific to Enlivex Therapeutics Ltd. (ENLV).
  • Interactive Dashboard and Visuals: Graphical representations provide a clear overview of essential valuation indicators for straightforward assessment.

How It Works

  • Step 1: Download the prebuilt Excel template featuring Enlivex Therapeutics Ltd. (ENLV) data.
  • Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
  • Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly see the recalculated results, including Enlivex's intrinsic value.
  • Step 5: Make well-informed investment decisions or create reports utilizing the outputs.

Why Choose This Calculator?

  • User-Friendly Interface: Perfect for both novice users and seasoned professionals.
  • Customizable Variables: Easily adjust inputs to tailor your financial analysis.
  • Real-Time Feedback: Observe immediate changes to Enlivex Therapeutics’ valuation as you modify inputs.
  • Preconfigured Data: Comes with Enlivex’s actual financial metrics for swift evaluations.
  • Relied Upon by Experts: Utilized by investors and analysts to guide their strategic decisions.

Who Should Use This Product?

  • Investors: Accurately estimate Enlivex Therapeutics Ltd.'s (ENLV) fair value before making investment decisions.
  • CFOs: Leverage a professional-grade DCF model for financial reporting and analysis specific to Enlivex Therapeutics Ltd. (ENLV).
  • Consultants: Quickly adapt the template for valuation reports tailored to Enlivex Therapeutics Ltd. (ENLV) for clients.
  • Entrepreneurs: Gain insights into financial modeling practices used by leading biotech firms like Enlivex Therapeutics Ltd. (ENLV).
  • Educators: Use it as a teaching tool to demonstrate valuation methodologies relevant to the biotech industry, including Enlivex Therapeutics Ltd. (ENLV).

What the Template Contains

  • Pre-Filled DCF Model: Enlivex Therapeutics Ltd.'s (ENLV) financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate Enlivex’s profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.

No products were found matching.